Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stage IB2 to IVA Uterine Cervical Cancer: Phase 2 Study to Assess a New Therapeutic Sequence Associating a Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine

NCT00421096 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT00421096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00421096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stage IB2 to IVA Uterine Cervical Cancer: Phase 2 Study to Assess a New Therapeutic Sequence Associating a Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2005
Completion date
December 31, 2011
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

uterine cervical cancer